Kaplan-Meier analysis also demonstrated that the S100A7+ group was significantly associated with poor clinical outcome in terms of both breast cancer-specific survival (P = 0.0101) and relapse-free survival (RFS) (P < 0.0001) (Fig. 4g and h). Here, S100A7 is linked to breast cancer.